Advertisement


W. Robert Lee, MD, on Prostate Cancer: Results of the NRG Oncology RTOG 0415 Study

2016 Genitourinary Cancers Symposium

Advertisement

W. Robert Lee, MD, of Duke University, discusses this phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer (Abstract 1).



Related Videos

Prostate Cancer

Paul L. Nguyen, MD, on Prostate Cancer: Results of the NRG Oncology/RTOG 9601 Study

Paul L. Nguyen, MD, of Dana-Farber Cancer Institute, discusses this phase III trial in which prostate cancer patients were given antiandrogen therapy with bicalutamide during and after salvage radiation therapy following radical prostatectomy and an elevated PSA (Abstract 3).

Kidney Cancer

Toni Choueiri, MD: Renal Cancer Update

Toni Choueiri, MD, of the Dana-Farber Cancer Institute, summarizes key points from a session he chaired on clear and non-clear cell renal cancer, including information on molecular genetics and its impact on treatment, how to treat patients with non-clear cell histology, and the best strategy for treating clear cell cancer.

Prostate Cancer

David P. Dearnaley, MD, on Prostate Cancer: Results from the CHHiP Trial

David P. Dearnaley, MD, of The Royal Marsden NHS Foundation Trust, discusses the comparison, in this study, of hypofractionated high-dose IMRT schedules for prostate cancer (Abstract 2).

Prostate Cancer

Maha Hussain, MD, on Prostate Cancer: Keynote Lecture

Maha Hussain, MD, of the University of Michigan, gives her expert perspective on changes in the treatment of hormone-naive disease.

Prostate Cancer

A. Oliver Sartor, MD, on Advanced Prostate Cancer: Predicting Treatment Resistance

A. Oliver Sartor, MD, of Tulane Cancer Center, discusses this study investigating circulating tumor cell characteristics to predict resistance to androgen deprivation therapies in patients with advanced prostate cancer (Abstract 163).

Advertisement

Advertisement




Advertisement